Filtered By:
Condition: Heart Failure
Procedure: Percutaneous Coronary Intervention

This page shows you your search results in order of date. This is page number 15.

Order by Relevance | Date

Total 490 results found since Jan 2013.

Use of TIMI Risk Index as a Simple and Valuable Prognostic Tool in Patients with ST-Segment Elevation Myocardial Infarction Who Underwent Primary Percutaneous Coronary Intervention
CONCLUSION: The results of this study indicated that Thrombolysis in Myocardial Infarction Risk Index value is an independent predictor of clinical outcomes such as death and heart failure but not subsequent myocardial infarction in ST-segment elevation myocardial infarction patients. The use of Thrombolysis in Myocardial Infarction Risk Index can be considered in ST-segment elevation myocardial infarction patients who underwent primary percutaneous coronary intervention as it is an easily applicable and important indicator of prognosis.PMID:35450843 | DOI:10.5543/tkda.2022.21143
Source: Turk Kardiyoloji Dernegi arsivi - April 22, 2022 Category: Cardiology Authors: İdris Buğra Çerik Ahmet Kaya Se çkin Dereli Fatih Akkaya Mustafa Yener çağ Osman Bekta ş Source Type: research

Early Experience with the HeartMate Percutaneous Heart Pump from the SHIELD II Trial
The HeartMate Percutaneous Heart Pump (PHP) is a novel circulatory support catheter delivering a self-expanding 24 French impeller across the aortic valve. The SHIELD II trial compares outcomes among heart failure patients undergoing high-risk percutaneous coronary intervention (HR-PCI) with the PHP versus Impella systems. The trial was halted in 2017 due to device malfunctions. We aimed to describe procedural, hemodynamic, and clinical outcomes among HR-PCI patients treated with PHP as part of the SHIELD II trial roll-in phase. Procedural, hemodynamic, and 90 day outcomes were assessed among patients undergoing HR-PCI wit...
Source: ASAIO Journal - April 1, 2022 Category: Medical Devices Tags: Adult Circulatory Support Source Type: research

A comparison of drug ‐eluting stent and coronary artery bypass grafting in mildly to moderately ischemic heart failure
ConclusionsConsidering the higher long-term survival rate and lower repeat-revascularization rate, CABG may be superior to DES implantation in patients with mildly to moderately reduced EF (35 –50%) and significant CAD.
Source: ESC Heart Failure - February 23, 2022 Category: Cardiology Authors: Kun Wang, Le Wang, Hongliang Cong, Jingxia Zhang, Yuecheng Hu, Yingyi Zhang, Rui Zhang, Wenyu Li, Wei Qi Tags: Original Article Source Type: research

In-hospital adverse events in low-risk patients with acute myocardial infarction - Potential implications for earlier discharge
CONCLUSION: In patients with acute MI with low GRACE and/or CADILLAC risk scores who were free from acute events within 3 days, early discharge after primary percutaneous coronary intervention may be feasible and safe.PMID:35078684 | DOI:10.1016/j.jjcc.2022.01.003
Source: Journal of Cardiology - January 26, 2022 Category: Cardiology Authors: Takanori Sato Yuichi Saito Tadahiro Matsumoto Daichi Yamashita Kan Saito Shinichi Wakabayashi Hideki Kitahara Koichi Sano Yoshio Kobayashi Source Type: research

Rural-Urban Disparities in Outcomes of Myocardial Infarction, Heart Failure, and Stroke in the United States
CONCLUSIONS: Clinical, public health, and policy efforts are needed to improve rural-urban gaps in care and outcomes for acute cardiovascular conditions.PMID:35057913 | DOI:10.1016/j.jacc.2021.10.045
Source: Rural Remote Health - January 21, 2022 Category: Rural Health Authors: Em éfah C Loccoh Karen E Joynt Maddox Yun Wang Dhruv S Kazi Robert W Yeh Rishi K Wadhera Source Type: research

Clinical Outcomes of Acute Myocardial Infarction Hospitalizations with Systemic Lupus Erythematosus: An Analysis of Nationwide Readmissions Database
CONCLUSION: Patients with AMI and SLE had higher inpatient mortality during the index hospitalization and higher 30-day hospital readmissions compared to AMI patients without SLE. There were no significant differences in most of the other major inpatient outcomes between the two cohorts.PMID:34936910 | DOI:10.1016/j.cpcardiol.2021.101086
Source: Atherosclerosis - December 22, 2021 Category: Cardiology Authors: Shazib Sagheer Pallav Deka Dola Pathak Umair Khan Syeda Humna Zaidi Anum Akhlaq James Blankenship Ann Annis Source Type: research

Effects of colchicine on major adverse cardiac events in next 6-month period after acute coronary syndrome occurrence; a randomized placebo-control trial
CONCLUSION: The addition of colchicine to standard medical therapy in ACS patients significantly reduces MACE occurrence and improves survival rate over the time.PMID:34876021 | DOI:10.1186/s12872-021-02393-9
Source: Atherosclerosis - December 8, 2021 Category: Cardiology Authors: Mehdi Akrami Peyman Izadpanah Mehdi Bazrafshan Unes Hatamipour Navid Nouraein Hamed Bazrafshan Drissi Alireza Manafi Source Type: research

Prognostic significance of Troponin I in patients undergoing primary percutaneous coronary intervention
Indian Heart J. 2021 Nov-Dec;73(6):737-739. doi: 10.1016/j.ihj.2021.09.004. Epub 2021 Sep 14.ABSTRACTThis observational study investigates the prognostic significance of troponin I in patients undergoing primary percutaneous intervention (pPCI). Sequential cardiac biomarker sampling of the enrolled patients (n = 167) was performed on admission and at 6,12,24 and 48 h. Clinical characteristics, major adverse cardiac and cerebrovascular events (MACCE) (death, reinfarction, stroke and new or worsening heart failure) and left ventricular ejection fraction (LVEF) were noted on admission and 30 day follow-up. A 24-h troponin I l...
Source: Indian Heart J - December 4, 2021 Category: Cardiology Authors: Pratik Sudhir Sane V Manoj Rufus Demel S Vijaykumar Ajit S Mullasari Source Type: research

Rating the importance of outcomes from diabetes trials. A survey of patients ’ and doctors’ opinions
ConclusionThe current study suggest that patients and doctors weigh some diabetic outcomes used as part of composite endpoints in clinical diabetes trials differently. These findings call for more studies on patient reported outcomes and patient education for improved personal care.Highlights• We performed this study to assess how patients and practicing physicians rate the importance of outcomes commonly used in diabetes trials.• We found that patients and doctors rate the importance of some outcomes used in clinical diabetes trials differently.• These findings suggest that shared decision making is pivotal when tak...
Source: Journal of Diabetes and Metabolic Disorders - November 25, 2021 Category: Endocrinology Source Type: research

Long ‐term impact of β‐blocker in elderly patients without myocardial infarction after percutaneous coronary intervention
ConclusionsLong-term β-blocker use was significantly associated with an increased risk of adverse cardiovascular events in elderly patients with CAD without MI or systolic HF. In particular, the chronotropic incompetence action of β-blockers could increase the risk of admission for HF in elderly patients with CAD with out MI and systolic HF, and the present findings warrant further investigation.
Source: ESC Heart Failure - November 23, 2021 Category: Cardiology Authors: Tatsuya Fukase, Tomotaka Dohi, Takuma Koike, Hidetoshi Yasuda, Mitsuhiro Takeuchi, Norihito Takahashi, Yuichi Chikata, Hirohisa Endo, Shinichiro Doi, Hiroki Nishiyama, Iwao Okai, Hiroshi Iwata, Shinya Okazaki, Katsumi Miyauchi, Hiroyuki Daid Tags: Original Article Source Type: research